<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513786</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-06133</org_study_id>
    <secondary_id>NCI-2012-01229</secondary_id>
    <nct_id>NCT00513786</nct_id>
  </id_info>
  <brief_title>Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma</brief_title>
  <official_title>A Phase II Study of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David O'Malley</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of this study is to determine the effectiveness of the drug combination carboplatin,
      paclitaxel, and bevacizumab(Avastin) in patients with advanced stage endometrial carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to test the effectiveness, safety, and tolerability of the drug
      combination carboplatin, paclitaxel, and bevacizumab(Avastin) in patients with advanced stage
      endometrial carcinoma. This is a phase II,open label,single center study. Patients will
      receive carboplatin, paclitaxel, and bevacizumab in an outpatient center by intravenous
      administration. The primary objectives is to study the progression free survival at 24 months
      after initiation of treatment and to determine the toxicity profile of the drug combinations.
      The secondary objectives are to estimate the overall survival and tumor response for this
      group of patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2007</start_date>
  <completion_date type="Actual">January 3, 2017</completion_date>
  <primary_completion_date type="Actual">January 3, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate patients with progression free survival (PFS)</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate overall survival and objective tumor response using modified RECIST (Response Evaluation Criteria in Solid Tumors) criteria</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse events as a measure of safety and tolerability.</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Toxicities will be assessed by using the NCI Common Toxicity Criteria for Adverse Events 3.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>carboplatin/paclitaxel with bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A regimen of Carboplatin and paclitaxel combined with bevacizumab given every 21 days in patients with advanced stage endometrial cancer for a maximum of 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.</description>
    <arm_group_label>carboplatin/paclitaxel with bevacizumab</arm_group_label>
    <other_name>Paraplatin</other_name>
    <other_name>CBDCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.</description>
    <arm_group_label>carboplatin/paclitaxel with bevacizumab</arm_group_label>
    <other_name>Onxol</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.</description>
    <arm_group_label>carboplatin/paclitaxel with bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced Stage Endometrial Cancer (Stage 3 or 4)

          -  Any Histology including clear cell, and serous papillary carcinomas

          -  surgery must have had hysterectomy and bilateral salpingo-oophorectomy

          -  chemotherapy initiated 12 weeks after surgery

          -  sign informed consent

          -  Adequate End-organ function

          -  GOG (Gynecologic Oncology Group)Performance Status 0,1,2

          -  Patients must be 18 years or older

          -  Patients may have received radiation for the treatment of endometrial cancer.

          -  Patients may have measurable or non-measurable disease.

        Exclusion Criteria:

          -  Patient with concomitant malignancy other than non-melanoma skin cancer

          -  Patients with prior malignancy who have been disease free for 5 years.

          -  Patients with serious uncontrolled infection, angina or serious peripheral neuropathy.

          -  Patients whose circumstances will not permit study completion or adequate follow up

          -  Patients who have received prior cytotoxic chemotherapy for treatment of endometrial
             cancer including chemotherapy used for radiation sensitization.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David O'Malley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ohio State University Division of Gyn Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University-Division of Gyn Oncology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>David O'Malley</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Advanced Stage Endometrial Cancer</keyword>
  <keyword>Stage 3 or 4 endometrial cancer</keyword>
  <keyword>Cancer treatment</keyword>
  <keyword>gyn cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

